Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

DOI

  1. Cardiovascular risk in Danish transgender persons: a matched historical cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Dynamic Changes in LH/FSH Ratios in Infants with Normal Sex Development

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin - physiology and pharmacology

    Publikation: Bidrag til tidsskriftReviewpeer review

  4. Randomized Controlled Trial of Tesomet for Weight Loss in Hypothalamic Obesity

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  1. Diagnostic and prognostic value of the electrocardiogram in stable outpatients with type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes

    Publikation: Bidrag til tidsskriftKommentar/debatpeer review

  3. Glucose-dependent insulinotropic polypeptide receptor antagonist studies in patients with type 2 diabetes

    Publikation: Bog/antologi/afhandling/rapportPh.d.-afhandlingForskning

Vis graf over relationer

Aims: The alpha-glucosidase inhibitor acarbose is believed to reduce plasma glucose by delaying hydrolysis of carbohydrates. Acarbose-induced transfer of carbohydrates to the distal parts of the intestine increases circulating glucagon-like peptide 1 (GLP-1). Using the GLP-1 receptor antagonist exendin(9-39)NH2, we investigated the effect of acarbose-induced GLP-1 secretion on postprandial glucose metabolism in patients with type 2 diabetes.

Methods: In a double-blinded, placebo-controlled, randomized, crossover study, 15 participants with metformin-treated type 2 diabetes (age: 57-85 years, HbA1c: 40-74 mmol/mol) were subjected to two 14-day treatment periods with acarbose or placebo, respectively, separated by a 6-week wash-out period. At the end of each period, two randomized 4-h liquid mixed meal tests with concomitant infusion of exendin(9-39)NH2 and saline, respectively, were performed.

Results: Compared to placebo, acarbose increased postprandial GLP-1 concentrations and decreased postprandial glucose. We observed no absolute difference in the exendin(9-39)NH2-induced increase in postprandial glucose excursions between placebo and acarbose periods, but relatively, postprandial glucose was increased by 119 ± 116% (mean ± s.d.) during exendin(9-39)NH2 infusion in the acarbose period vs a 39 ± 27% increase during the placebo period (P = 0.0163).

Conclusions: We confirm that acarbose treatment stimulates postprandial GLP-1 secretion in patients with type 2 diabetes. Using exendin(9-39)NH2, we did not see an impact of acarbose-induced GLP-1 secretion on absolute measures of postprandial glucose tolerance, but relatively, the effect of exendin(9-39)NH2 was most pronounced during acarbose treatment.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Endocrinology
Vol/bind184
Udgave nummer3
Sider (fra-til)383-394
Antal sider12
ISSN0804-4643
DOI
StatusUdgivet - mar. 2021

ID: 61868796